Licensing status

Publication and contact information

Endocrine/metabolic disease

Diabetes; obesity

HNF1 homeobox B
(HNF1B); microRNA-802 (miR-802)

Mouse and human studies suggest inhibiting miR-802 or increasing HNF1B signaling could help treat obesity and type 2 diabetes. In overweight humans and in genetic and diet-induced obesity mouse models, miR-802 expression was greater in the liver than that in livers from lean individuals and nonobese control mice. In the mouse obesity models, locked nucleic acid (LNA) antagonists of miR-802 expression increased insulin resistance and glucose tolerance compared with control LNAs. In the mouse models, vector-induced overexpression of Hnf1b, the identified target of miR-802, also improved insulin resistance and glucose tolerance. Next steps could include developing a screen to identify molecules that inhibit miR-802 and/or promote HNF1B signaling.

SciBX 6(8); doi:10.1038/scibx.2013.195
Published online Feb. 28, 2013

Patent and licensing status unavailable

Kornfeld, J.-W. et al. Nature; published online Feb. 6, 2013;
Contact: Jens Brüning, Max Planck Institute for Neurological Research, Cologne, Germany